Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Oxford BioDynamics ( (GB:OBD) ) has provided an announcement.
Oxford BioDynamics Plc announced its preliminary results for the year ending September 2024, highlighting significant corporate and operational developments. The company achieved a CPT-PLA Code for its EpiSwitch PSE Test, enabling reimbursement by US insurers, and opened a UK Clinical Laboratory. Despite an operating loss of £12.9m, the company raised substantial funds to support its ongoing operations. Post-year-end, Oxford BioDynamics secured a distribution agreement with Romania’s largest private healthcare provider and presented real-world data on its EpiSwitch CiRT at a major conference. The company plans to focus on partnerships and collaborations to enhance commercial success and shareholder value.
More about Oxford BioDynamics
Oxford BioDynamics Plc is a precision clinical diagnostics company that specializes in developing specific and sensitive tests based on its EpiSwitch® 3D genomics platform. The company focuses on providing innovative diagnostic solutions in the medical field, with a market emphasis on genomic testing for various cancers.
YTD Price Performance: -62.33%
Average Trading Volume: 18,762,358
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £11.06M
Find detailed analytics on OBD stock on TipRanks’ Stock Analysis page.